Long-term follow-up for patients with wet age-related macular degeneration receiving SKG0106
Official title: A Prospective, Non-interventional, Multicenter, Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With Neovascular (Wet) Age-related Macular Degeneration (nAMD)
Run by Skyline Therapeutics · NCT06346600 · Data updated 2026-11-12
This study is testing how well and safely the treatment SKG0106 works for people with wet age-related macular degeneration over a long period after their last injection.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 50 Years and up |
| Sex | All |
| Enrollment | 83 (estimated) |
| Sponsor | Skyline Therapeutics Industry-sponsored |
| Locations | 10 sites (Boston, Massachusetts and 9 other locations) |
| Status | Recruiting |
| Started | April 2, 2025 |
| Main results expected | March 2031 |
| Study ends | March 2031 |
| Registry record updated | September 1, 2026 |
| Trial ID | NCT06346600 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients who have previously received SKG0106 injections and completed the related clinical studies.
✕Probably not a fit
Patients who have not received SKG0106 or those deemed unsuitable by the investigator will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study evaluates the long-term safety and efficacy of SKG0106 in patients with neovascular (wet) age-related macular degeneration (nAMD) who have previously participated in related clinical studies. Participants will be monitored for up to five years following their last injection of SKG0106 to assess ongoing treatment effects. The study aims to gather data on the long-term outcomes of this treatment in a multicenter setting.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the long-term effectiveness and safety of SKG0106 for patients with nAMD.
How similar studies have gone: Other studies evaluating long-term outcomes of treatments for nAMD have shown promising results, suggesting that this approach may yield valuable data.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Subjects who only meet all of the following criteria are eligible for this study: * nAMD subjects who have been enrolled in the SKG0106-related study and received SKG0106 injection; * Subjects who voluntarily sign an informed consent form (ICF) and comply with the protocol to complete the study Exclusion Criteria: * Subjects who are judged by the investigator unsuitable for this study
Where it's running
-
Peking Union Medical College Hospital
Beijing, China Recruiting -
EYE & ENT Hospital of Fudan University
Shanghai, China Recruiting -
Ophthalmic Consultants of Boston
Boston, Massachusetts, United States Not yet recruiting -
Retina Consultants of Texas
Katy, Texas, United States Not yet recruiting -
Wagner Macula & Retina Center
Norfolk, Virginia, United States Not yet recruiting -
The Second Hospital Of Anhui Medical University
Hefei, Anhui, China Not yet recruiting
Show 4 more locations
-
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China Not yet recruiting -
Eye Hospital, WMU (Zhejiang Eye Hospital)
Wenzhou, Zhejiang, China Not yet recruiting -
Beijing Hospital
Beijing, China Not yet recruiting -
Xinhua Hospital Affiliated To Shanghai Jiao Tong University School Of Medicine
Shanghai, China Not yet recruiting
Study contacts
- Study coordinator: Eddy Anglade, MD
- Email: eanglade@focusbiosciences.com
- Phone: +1-908-884-1246
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
EYC-0305 in Neovascular (Wet) AMD: First-in-Patients Safety and Tolerability Study
This study tests whether EYC-0305 given as an eye injection every 24 weeks is safe and tolerable in people 50 and older with wet AMD.
-
AIV007 Periocular Shot for Wet AMD
This trial tests whether a periocular injection of AIV007 can improve vision and safety in people with wet age-related macular degeneration, compared with the standard Eylea injections.
-
Treatment for wet age-related macular degeneration using 4D-150
This study is testing a new gene therapy called 4D-150 to see if it can improve vision in adults with wet age-related macular degeneration who are already receiving other treatments.
-
JWK001 subretinal therapy for neovascular AMD
This study tests a single subretinal dose of JWK001 at different levels in people with wet age-related macular degeneration who have previously responded to anti-VEGF treatment.
-
Ixo-vec Contralateral Dosing in Bilateral Wet AMD
Researchers are testing whether giving Ixo-vec to the second eye of adults with bilateral wet AMD is safe and helps vision over time.
-
Using OCT Angiography to Diagnose and Evaluate Wet AMD
This study is testing if a special imaging technique can help doctors find new blood vessels in older adults with wet age-related macular degeneration and see how blood flow might affect the condition.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.